Kayanna Jonas
Psychiatric/Mental Health · Far Rockaway, NYNPI 1538674619
Payments from drug & device makers
Across 792 payments — averaging $117.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$36K
- Teva Pharmaceuticals USA, Inc.$23K
- Alkermes, Inc.$22K
- E.r. Squibb & Sons, L.L.C.$5K
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- plus $3K from 8 others
What the payments were for
- Consulting fees$15,94517%
- Speaking & faculty fees$47,94352%
- Travel & lodging$8,3559%
- Food & beverage$20,09922%
- Education$4701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 167 | $35,944 |
| Teva Pharmaceuticals USA, Inc. | 190 | $23,363 |
| Alkermes, Inc. | 115 | $21,622 |
| E.r. Squibb & Sons, L.L.C. | 47 | $4,863 |
| AbbVie | 94 | $2,359 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 69 | $1,666 |
| Otsuka America Pharmaceutical, Inc. | 56 | $1,531 |
| Johnson & Johnson | 23 | $693 |
| Vanda Pharmaceuticals Inc. | 9 | $219 |
| Axsome Therapeutics, Inc. | 6 | $185 |
| Sunovion Pharmaceuticals Inc. | 6 | $141 |
| Lundbeck LLC | 6 | $139 |
| Indivior Inc. | 2 | $51 |
| Validus Pharmaceuticals LLC | 2 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$64,043
- INGREZZA$32,699
- UZEDY$15,880
- ARISTADA$13,711
- ARISTADA INITIO$3,428
- COBENFY$3,270
- Austedo XR$2,476
- VRAYLAR$478
- CAPLYTA$384
- AUSTEDO$364
- ABILIFY MAINTENA$230
- REXULTI$125
- ABILIFY ASIMTUFII$117
How this compares
$92,812 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 46 | $361,217 |
| Invega TrinzaPaliperidone Palmitate | 34 | $318,502 |
| LybalviOlanzapine/Samidorphan Malate | 136 | $221,373 |
| UzedyRisperidone | 74 | $175,666 |
| AristadaAripiprazole Lauroxil | 42 | $160,947 |
| Invega SustennaPaliperidone Palmitate | 43 | $116,596 |
| Austedo XrDeutetrabenazine | 12 | $91,846 |
| AustedoDeutetrabenazine | 12 | $90,579 |
| VraylarCariprazine Hcl | 48 | $68,262 |
| Abilify MaintenaAripiprazole | 23 | $64,098 |
| CaplytaLumateperone Tosylate | 37 | $61,707 |
| RexultiBrexpiprazole | 28 | $41,908 |
| Divalproex Sodium | 280 | $7,659 |
| Clozapine | 117 | $7,300 |
| Aripiprazole | 181 | $6,419 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $693 | $435,09777 claims |
| Alkermes, Inc.Lybalvi, Aristada | $21,622 | $382,320178 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $35,944 | $361,21746 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy, Austedo Xr, Austedo | $23,363 | $358,09198 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,531 | $106,00551 claims |
| AbbVieVraylar | $2,359 | $68,26248 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,666 | $61,70737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Far Rockaway
- Glenn HannDansville$1.3M
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Mary OlsonNew York$142K
- Elijah StevensBinghamton$131K
- Alexis CrisafiFishkill$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.